MINI REVIEW

The Importance of Genetic Diagnostic Modalities in Gaucher Disease

Vaibhav Gode*

Abstract

Gaucher disease (GD) is a rare lysosomal storage disorder due to a deficiency in the enzyme acid β-glucosidase (GCase), which leads to the accumulation of glucosylceramide in various body tissues. This autosomal recessive disorder is primarily associated with pathogenic variants in the GBA1 gene. Accurate and timely diagnosis of GD is essential for effective management and treatment. This article reviews the role of genetic diagnostic modalities in diagnosing GD, highlighting recent advancements and their clinical implications. Various genetic testing techniques, including Sanger sequencing, next-generation sequencing (NGS), and single molecule real-time (SMRT) sequencing are discussed in this article. Each method offers unique advantages and challenges, particularly in distinguishing between the GBA1 gene and its pseudo-gene. The clinical utility of genetic testing extends to early diagnosis and treatment initiation, risk assessment, and guiding therapeutic decisions based on specific GBA1 variants. Challenges such as the complexity of the GBA1 gene, the classification of variants of uncertain significance (VUS), and ethical considerations are also addressed in this study. Ongoing research and advancements in genetic testing technologies aim to improve the accuracy, accessibility, and clinical utility of genetic testing for GD. This review underscores the importance of genetic diagnostic modalities in comprehensive management of Gaucher disease.

Keywords: Gaucher Disease, Genetic Testing, GBA1 Gene Next-Generation Sequencing, Enzyme Replacement Therapy.

Journal of Research in Medical & Interpathy Sciences. 2(1);2024

Introduction

Gaucher disease (GD) is a rare lysosomal storage disorder caused by a deficiency in the enzyme acid β-glucosidase (GCase), which breaks down glucosylceramide into glucose and ceramide. This deficiency leads to the accumulation of glucosylceramide in various body tissues, resulting in a wide range of clinical manifestations.[1] The disease is inherited in an autosomal recessive manner, and it is most commonly associated with pathogenic variants in the GBA1 gene.[2]

Given the complexity and variability of Gaucher disease, accurate and timely diagnosis is crucial for effective management and treatment. Genetic diagnostic modalities play a pivotal role in diagnosing GD, providing essential information for patient management and family counseling. This article aims to highlight the importance of these modalities in the context of GD, drawing on recent guidelines and research findings.

Overview of Gaucher Disease

Gaucher disease is classified into three main types based on clinical presentation and severity[1]-

a) **Type 1 (Non-neuronopathic):** This is the most common form, characterized by symptoms such as hepatosplenomegaly, anaemia, thrombocytopenia, and bone disease. Neurological involvement is absent.
b) **Type 2 (Acute neuronopathic):** This form is rare and severe, presenting in infancy with rapid neurological decline, leading to death typically before two years of age.
c) **Type 3 (Chronic neuronopathic):** This form presents with variable neurological involvement and can have a slower progression compared to type 2. It often includes systemic manifestations similar to type 1.

Department of Pediatrics, SMBT Institute of Medical Science & Research Centre, Nashik, Maharashtra, India

Corresponding Author: Vaibhav Gode, Department of Pediatrics, SMBT Institute of Medical Science & Research Centre, Nashik, Maharashtra, India. Email: vaibahvgode@gmail.com

Conflict of Interest: None

Source of Funding: None

Biochemical and Genetic Basis of GD

The GBA1 gene, located on chromosome 1q21, encodes the GCase enzyme. Pathogenic variants in this gene result in deficient enzyme activity, leading to the characteristic accumulation of glucosylceramide. The GBA1 gene has a nearby pseudogene (GBAP) with high sequence homology which complicates genetic analysis due to potential gene-pseudogene recombination events.

Role of Genetic Testing in GD Diagnosis

Genetic testing is indispensable for confirming GD diagnosis, especially when enzyme assays yield ambiguous results. Here are key aspects of genetic testing in the context of GD:

1. **Confirmatory Diagnosis:** Identifying biallelic pathogenic variants in the GBA1 gene confirms GD diagnosis.[3] This is particularly important when biochemical assays for GCase

activity are inconclusive or when atypical presentations occur.

2. **Genetic Counselling:** Genetic testing provides critical information for genetic counseling, enabling informed reproductive choices for affected families. Carrier testing and prenatal diagnosis can be offered to at-risk individuals.[4]
3. **Variant Classification:** Variants in GBA1 are classified according to the American College of Medical Genetics (ACMG) criteria. This classification helps in determining the pathogenicity of identified variants, especially those of uncertain significance (VUS).[5]
4. **Molecular Analysis Techniques:** Long-template PCR amplification and Sanger sequencing are traditionally used to identify single nucleotide variants and small indels in GBA1. Next-generation sequencing (NGS) technologies, including whole exome sequencing (WES) and whole genome sequencing (WGS), offer comprehensive analysis but require careful handling to avoid misalignment issues with the pseudogene.[5]

Genetic Testing Modalities

1. **Sanger Sequencing:** Sanger sequencing remains a gold standard for detecting specific mutations in the GBA1 gene. This method is highly accurate in identifying single nucleotide variants and small deletions/insertions.[6] However, it is labor-intensive and less efficient for large-scale screening or detecting large deletions and complex rearrangements.
2. **Next-Generation Sequencing (NGS):** NGS technologies have revolutionized genetic testing by allowing the simultaneous analysis of multiple genes. In the context of GD, NGS can be employed to sequence the GBA1 gene comprehensively.[7] However, specific challenges arise due to the high homology between GBA1 and its pseudogene. Strategies to mitigate these challenges include:
3. **Targeted NGS Panels:** These panels are designed to capture and sequence only the GBA1 gene, excluding the pseudogene regions.[8] This approach enhances the accuracy of variant detection.
4. **Whole Exome Sequencing (WES):** WES provides a broader analysis, capturing all coding regions of the genome.[9] While it can identify variants in GBA1, careful data analysis can distinguish between gene and pseudogene.
5. **Whole Genome Sequencing (WGS):** WGS offers the most comprehensive analysis, capturing both coding and non-coding regions. However, it is the most resource-intensive and requires advanced bioinformatics tools for accurate data interpretation.[9]
6. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA is a robust technique for detecting large deletions, duplications, and complex rearrangements in the GBA1 gene. It is particularly useful when traditional sequencing methods fail to identify pathogenic variants. MLPA can differentiate between common mutations and recombinant alleles, providing valuable information for genetic diagnosis.[10]
7. **Single-Molecule Real-Time (SMRT) Sequencing:** SMRT sequencing, developed by PacBio, is an emerging technology that offers long-read sequencing capabilities. This method can provide detailed information on complex genomic regions, including those involving gene-pseudogene recombination events. Although not yet widely available, SMRT sequencing holds promise for future applications in GD genetic testing.[11]

Clinical Utility of Genetic Testing

Early Diagnosis and Treatment Initiation

Early diagnosis of GD through genetic testing allows for timely initiation of treatment, which can significantly improve patient outcomes.[12] Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are available treatments that can ameliorate symptoms and prevent disease progression. Genetic testing facilitates early identification of affected individuals, enabling prompt therapeutic intervention.

Risk Assessment and Family Screening

Genetic testing enables the identification of carriers within affected families, providing crucial information for risk assessment and family planning.[6] Carrier screening can help identify at-risk individuals who may benefit from genetic counseling and prenatal testing options.

Guiding Therapeutic Decisions

Specific GBA1 variants are associated with different clinical phenotypes and responses to therapy. Genetic testing can guide therapeutic decisions by identifying variants that may predict disease severity or therapeutic response.[6,12] As an example, the N370S variant is commonly associated with milder type 1 GD, while the L444P variant is linked to more severe neuronopathic forms.

Challenges and Considerations in Genetic Testing

Complexity of the GBA1 Gene and Pseudogene

The high sequence homology between the GBA1 gene and its pseudogene complicates genetic testing. Accurate differentiation between the gene and pseudogene is essential to avoid false-positive or false-negative results.[6] Advanced sequencing technologies and bioinformatics tools are required to address these challenges.

Variants of Uncertain Significance (VUS)

The identification of VUS poses a significant challenge in genetic testing. Functional studies and segregation analysis are necessary to determine the pathogenicity of these variants.[13] Collaborative efforts between clinical laboratories and research institutions are essential to gather sufficient evidence for variant classification.

Ethical and Psychosocial Considerations

Genetic testing for GD raises ethical and psychosocial issues, including the potential for anxiety and distress among patients and their families. Pre- and post-test genetic counseling by experienced professionals is crucial to ensure informed decision-making and provide emotional support.

Future Directions and Research

Development of New Genetic Testing Methods

Ongoing research aims to develop new genetic testing methods that are more accurate, cost-effective, and accessible. Advances in long-read sequencing technologies and bioinformatics tools hold promise for improving the detection of complex variants in the GBA1 gene. Additionally, efforts are underway to develop point-of-care genetic testing platforms that can provide rapid and accurate results.

Conclusion

Genetic diagnostic modalities are indispensable in the diagnosis and management of Gaucher disease. These modalities provide critical information for confirming diagnosis, guiding therapeutic decisions, and offering genetic counseling to affected families. Advances in genetic testing technologies, such as NGS and SMRT sequencing, have enhanced our ability to detect and characterize pathogenic variants in the GBA1 gene. However, challenges remain, including the complexity of the GBA1 gene and pseudogene, the classification of VUS, and the ethical implications of genetic testing. Ongoing research and collaborative efforts are essential to address these challenges and improve the accuracy, accessibility, and clinical utility of genetic testing for GD.

References

1. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005 Apr;129(2):178–88. *DOI: 10.1111/j.1365-2141.2004.05351.x*
2. Pastores GM, Weinreb NJ, Aerts H, Andria G, et al. Therapeutic Goals in the Treatment of Gaucher Disease. Seminars in Hematol. 2004;41(5):4–14. *https://doi.org/10.1053/j.seminhematol.2004.07.009*
3. Cox TM, Schofield JP. 3 Gaucher's disease: clinical features and natural history. Baillières Clin Hwaematol. 1997 Dec 1;10(4):657–89. *https://doi.org/10.1016/S0950-3536(97)80033-9*
4. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat. 2010 Nov;31(11):1240–50. *https://doi.org/10.1002/humu.21327*
5. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015 May;17(5):405–24. *https://doi.org/10.1002/humu.21327*
6. Dardis A, Michelakakis H, Rozenfeld P, Fumic K, Wagner J, Pavan E, et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis [Internet]. 2022 [cited 2024 May 30];17. *https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768924/*
7. Woo EG, Tayebi N, Sidransky E. Next-Generation Sequencing Analysis of GBA1: The Challenge of Detecting Complex Recombinant Alleles. Front Genet. 2021 Jun 21;12:684067. *doi: 10.3389/fgene.2021.684067*
8. Málaga DR, Brusius-Facchin AC, Siebert M, Pasqualim G, Saraiva-Pereira ML, de Souza CFM, et al. Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders. Genet Mol Biol. 2019;42(1 Suppl 1):197–206. *doi: 10.1590/1678-4685-GMB-2018-0092*
9. Kishikawa T, Momozawa Y, Ozeki T, Mushiroda T, Inohara H, Kamatani Y, et al. Empirical evaluation of variant calling accuracy using ultra-deep whole-genome sequencing data. Sci Rep. 2019 Feb 11;9:1784. *doi: 10.1038/s41598-018-38346-0*
10. Amico G, Grossi S, Vijzelaar R, Lanza F, Mazzotti R, Corsolini F, et al. MLPA-based approach for initial and simultaneous detection of GBA deletions and recombinant alleles in patients affected by Gaucher Disease. Mol Genet Metab. 2016 Oct 1;119. *DOI:10.1016/j.ymgme.2016.10.008*
11. Drelichman GI, Fernández Escobar N, Soberon BC, Basack NF, Frabasil J, Schenone AB, et al. Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease. Mol Genet Metab Rep. 2021 Nov 11;29:100820. *doi: 10.1016/j.ymgmr.2021.100820*
12. Zimran A. How I treat Gaucher disease. Blood. 2011 Aug 11;118(6):1463–71. https://doi.org/10.1182/blood-2011-04-308890
13. Filocamo M, Mazzotti R, Stroppiano M, Seri M, Giona F, Parenti G, et al. Analysis of the glucocerebrosidase gene and mutation profile in 144 Italian gaucher patients. Hum Mutat. 2002 Sep;20(3):234–5. *DOI: 10.1002/humu.9058*